FI954773A7 - Antihypertriglyserideeminen koostumus - Google Patents

Antihypertriglyserideeminen koostumus Download PDF

Info

Publication number
FI954773A7
FI954773A7 FI954773A FI954773A FI954773A7 FI 954773 A7 FI954773 A7 FI 954773A7 FI 954773 A FI954773 A FI 954773A FI 954773 A FI954773 A FI 954773A FI 954773 A7 FI954773 A7 FI 954773A7
Authority
FI
Finland
Prior art keywords
antihypertriglyceridemic
composition
antihypertriglyceridemic composition
Prior art date
Application number
FI954773A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI954773A0 (fi
Inventor
Yasuo Sugiyama
Hidefumi Yukimasa
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of FI954773A0 publication Critical patent/FI954773A0/fi
Publication of FI954773A7 publication Critical patent/FI954773A7/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
FI954773A 1994-10-07 1995-10-06 Antihypertriglyserideeminen koostumus FI954773A7 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP24413694 1994-10-07

Publications (2)

Publication Number Publication Date
FI954773A0 FI954773A0 (fi) 1995-10-06
FI954773A7 true FI954773A7 (fi) 1996-04-08

Family

ID=17114301

Family Applications (1)

Application Number Title Priority Date Filing Date
FI954773A FI954773A7 (fi) 1994-10-07 1995-10-06 Antihypertriglyserideeminen koostumus

Country Status (11)

Country Link
EP (1) EP0705607A2 (OSRAM)
KR (1) KR960013370A (OSRAM)
CN (1) CN1128657A (OSRAM)
AU (1) AU703422B2 (OSRAM)
CA (1) CA2160092A1 (OSRAM)
FI (1) FI954773A7 (OSRAM)
HU (1) HUT73422A (OSRAM)
NO (1) NO308580B1 (OSRAM)
NZ (1) NZ280165A (OSRAM)
RU (1) RU2166320C2 (OSRAM)
TW (1) TW401301B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2158344T3 (es) * 1995-09-13 2001-09-01 Takeda Chemical Industries Ltd Compuestos benzoxazepinicos, su produccion y uso como agentes reductores de lipidos.
CN1072649C (zh) * 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
WO1997047323A2 (en) * 1996-06-11 1997-12-18 Zonagen, Inc. Chitosan drug delivery system
ATE309993T1 (de) 1997-04-21 2005-12-15 Takeda Pharmaceutical 4,1-benzoxazepine, ihre analoga, und ihre verwendung als somatostatin-agonisten
JP4204657B2 (ja) * 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
US6214991B1 (en) 1998-03-31 2001-04-10 The Institute For Pharmaceutical Discovery, Inc. Substituted indolealkanoic acids
US6207664B1 (en) 1998-11-25 2001-03-27 Pfizer Inc. Squalene synthetase inhibitor agents
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
CA2370141A1 (en) 1999-05-26 2000-12-07 James D. Rodgers 1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors
MXPA02001340A (es) * 1999-08-05 2004-07-16 Prescient Neuropharma Inc Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos.
WO2002038180A1 (en) * 2000-11-09 2002-05-16 Takeda Chemical Industries, Ltd. High-density lipoprotein-cholesterol level elevating agent
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US20040204500A1 (en) * 2001-06-28 2004-10-14 Yasuo Sugiyama Preventives/remedies for organ functional disorders and organ dysfunction
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US7625887B2 (en) 2003-01-28 2009-12-01 Takeda Pharmaceutical Company Limited Receptor agonists
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
CA2575014A1 (en) * 2004-08-09 2006-02-16 Takeda Pharmaceutical Company Limited Crp lowering agent
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
JP2009512715A (ja) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト レニン阻害剤と抗異脂肪血症剤および/または抗肥満症剤の組み合わせ
JP2010526825A (ja) 2007-05-10 2010-08-05 エーエムアール テクノロジー インコーポレイテッド アリール置換およびヘテロアリール置換テトラヒドロベンゾ−1,4−ジアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
EP4146205A4 (en) 2020-05-05 2024-05-29 Nuvalent, Inc. HETEROAROMATIC MACROCYCLIC ETHERS AS CHEMOTHERAPEUTIC AGENTS
IL297832A (en) 2020-05-05 2023-01-01 Nuvalent Inc Macrocyclic heteroaromatic chemotherapeutic agents
TW202320768A (zh) 2021-10-01 2023-06-01 美商努法倫特公司 雜芳族大環醚化合物之固體形式、醫藥組成物及製備

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180717A (en) * 1988-08-16 1993-01-19 The Upjohn Company Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol
FR2659332B1 (fr) * 1990-03-08 1994-04-29 Adit Et Cie Nouvelles pyrrolo [1,2-a] thieno [3,2-f] diazepines [1,4], leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
EP0567026B1 (en) * 1992-04-20 2003-03-26 Takeda Chemical Industries, Ltd. 4,1-Benzoxazepin derivatives as squalene synthase inhibitors and their use in the treatment of hypercholesteremia and as fungicides
TW225992B (OSRAM) * 1992-07-17 1994-07-01 Senju Pharma Co
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
WO1995021834A1 (en) * 1994-02-09 1995-08-17 Takeda Chemical Industries, Ltd. Optically active 4,1-benzoxazepine derivatives useful as squalene synthase inhibitors

Also Published As

Publication number Publication date
FI954773A0 (fi) 1995-10-06
HUT73422A (en) 1996-07-29
NO308580B1 (no) 2000-10-02
EP0705607A3 (OSRAM) 1996-05-08
HU9502918D0 (en) 1995-11-28
CA2160092A1 (en) 1996-04-08
AU703422B2 (en) 1999-03-25
KR960013370A (ko) 1996-05-22
RU2166320C2 (ru) 2001-05-10
NZ280165A (en) 1997-07-27
NO953961D0 (no) 1995-10-05
EP0705607A2 (en) 1996-04-10
NO953961L (no) 1996-04-09
AU3308195A (en) 1996-04-18
CN1128657A (zh) 1996-08-14
TW401301B (en) 2000-08-11

Similar Documents

Publication Publication Date Title
DE69526966D1 (de) Hautkräftigende kometische zusammensetzung
DE69718508D1 (de) Antitraspirant zusammensetzung
DE69516018D1 (de) Verdickte persäurezusammensetzungen
FI954008L (fi) Substituoituja bifenyyli-isoksatsolisulfoniamideja
FI951908A7 (fi) Substituoituja pyridyylipyratsoleja
NO985460D0 (no) Limsammensetning
FI955927A0 (fi) Substituoidut 1H-imidatsolit
BR9508318A (pt) Composição impadora concentrada
DE69534718D1 (de) Substituierte 9-alkyladenine
FI954773A7 (fi) Antihypertriglyserideeminen koostumus
ID18359A (id) Komposisi mikrokapsul
BR9606809A (pt) Composição inseticidamente ativa
FI942119A0 (fi) Anordning i en gasblandare
BR9607058A (pt) Composição
ID19589A (id) Komposisi
PT728814E (pt) Composicao betuminosa
BR9609903A (pt) ComposiçÃo inseticidamente ativa
BR9707835A (pt) Composiç
ITMI940362A0 (it) Composizione antitosse
BR9509899A (pt) Composição modificadora de sabor
DE69616374D1 (de) Germizide zusammensetzung
MA23731A1 (fr) Compositions detegentes
BR9709815A (pt) Composicão
BR9607946A (pt) Composição
KR950033309U (ko) 줄연장